Compass Pathways/$CMPS
1D1W1MYTD1Y5YMAX
Capital at risk
About Compass Pathways
Compass Pathways PLC is a biotechnology company focused on developing therapies for mental health conditions. Its research centers on a proprietary synthetic psilocybin formulation, COMP360, which is administered alongside psychological support. The company is conducting clinical trials to evaluate the safety and efficacy of this treatment in patients with treatment-resistant depression and other mental health disorders. The company operates in one operating segment.
- Ticker
- $CMPS
- Sector
- Health
- Primary listing
- NASDAQ
- Employees
- 156
- Headquarters
- London, United Kingdom
- Website
- compasspathways.com
Compass Pathways Metrics
BasicAdvanced
$1.7B
-
-$3.61
2.53
-
Price and volume
Market cap
$1.7B
Beta
2.53
52-week high
$15.87
52-week low
$4.88
Average daily volume
2.7M
Financial strength
Current ratio
1.295
Quick ratio
1.221
Long term debt to equity
0.624
Total debt to equity
0.646
Interest coverage (TTM)
-35.78%
Profitability
EBITDA (TTM)
-185.563
Effective tax rate (TTM)
0.67%
Management effectiveness
Return on assets (TTM)
-29.08%
Return on equity (TTM)
-319.07%
Valuation
Price to book
19.19
Price to tangible book (TTM)
19.19
Price to free cash flow (TTM)
-8.099
Free cash flow yield (TTM)
-12.35%
Free cash flow per share (TTM)
-1.476
Growth
Earnings per share change (TTM)
109.03%
3-year earnings per share growth (CAGR)
15.49%
What the Analysts think about Compass Pathways
Analyst ratings (Buy, Hold, Sell) for Compass Pathways stock.
Analyst projections of the future price of Compass Pathways stock.
Bulls say / Bears say
Compass reported positive results from both pivotal Phase 3 TRD trials, with COMP360 showing rapid onset and durable benefit through at least 26 weeks in the second trial—substantially reducing clinical-development risk. (Compass Pathways)
The FDA granted a rolling NDA submission and review request, and Compass received a Commissioner’s National Priority Review Voucher, potentially accelerating the regulatory path toward a first-half 2027 commercial launch. (Compass Pathways)
Compass ended the second quarter with $433 million in cash and expects funding to extend beyond launch and into 2028, giving it more flexibility to complete regulatory work, prepare commercialization, and advance its late-stage PTSD program. (Compass Pathways)
COMP360 still requires FDA approval: Compass’s rolling NDA review is underway, but the final submission is only expected in Q4 2026, leaving meaningful regulatory and timing risk before the targeted first-half 2027 launch. (SEC)
The commercialization model is operationally demanding because Compass must identify, qualify, train, and support third-party treatment sites, while DEA scheduling, controlled-substance compliance, and site certification could delay uptake or increase costs. (SEC)
Despite $433.3 million of cash at June 30, 2026, Compass reported a $162.6 million six-month net loss and warns that additional financing may be required; future equity or warrant issuance could materially dilute shareholders. (SEC)
Data summarised monthly by Lightyear AI. Last updated on 9 Sept 2026.
Compass Pathways Financial Performance
Revenues and expenses
Compass Pathways Earnings Performance
Company profitability
Upcoming events
No upcoming events
Compass Pathways News
AllArticlesVideos
Funds containing Compass Pathways
AllUSDGBP
Fund name | Fund size | $CMPS weighting |
|---|---|---|
iShares Nasdaq US Biotechnology$BTEC | $1.2B | 0.11% |
iShares Nasdaq US Biotechnology£BTEK | £865M | 0.11% |
Data displayed above is indicative only and its accuracy or completeness is not guaranteed. Actual execution price may vary. Past performance is not indicative of future results. Your return may be affected by currency fluctuations and applicable fees and charges. Capital at risk.
Real-time US market data is sourced from the IEX order book provided by Polygon. After-hours US market data is 15 minutes delayed and may differ significantly from the actual tradable price at market open.